DRUG STUDY: NCM 106 PHARMACOLOGY Instructor: _______________________________________ Date: ________________________
NAME: ____________________________________________________________ BLOCK and Year:___________________________Group: ______________________________
DRUG NAME MECHANISM OF INDICATION CONTRAINDICATION ADVERSE EFFECTS NURSING INTERVENTIONS
ACTION
Generic Name: Exerts antiviral effect CMV retinitis in AIDS Hypersensitivity to drug, CNS: headache, seizures, Patient monitoring:
cidofovir by interfering with patients probenecid, or other sulfa- coma Assess white blood cell
DNA synthesis of containing agents EENT: decreased count and creatinine and
CMV, thereby Creatininelevelabove1.5mg/ intraocular pressure urine protein levels
inhibiting viral dl, calculated creatinine GI: nausea, vomiting, within 48 hours of each
replication diarrhea, anorexia, oral dose.
clearance of 55 ml/ minute
candidiasis
Drug Classification: or less, or urine protein Closely monitor
GU: proteinuria,
Antiviral level of 100 mg/dl or higher nephrotoxicity intraocular pressure and
Concurrent use of Hematologic: neutropenia visual acuity.
nephrotoxic drugs Hepatic: hepatomegaly Monitor hepatic enzyme
Metabolic: metabolic levels in patients with
acidosis hepatic disease.
Musculoskeletal: muscle
contractions Patient teaching:
Available Dosage: Respiratory: dyspnea, Tell patient to
CMV retinitis in increased cough immediately report
AIDS patients Skin: rash, alopecia fever, vision
Adults: 5 mg/kg I.V. Other: pain, fever, chills, changes, nausea,
infused over 1 hour infection, pain at I.V. site vomiting, rash, or
q week for 2 urinary output
continuous weeks; changes.
then 5 mg/kg I.V. Instruct patient to
once q 2 weeks as a take probenecid, as
maintenance dose prescribed, before
each dose and to
have regular eye
examinations.
Urge female patient
of childbearing age
to use effective
contraception during
and for 1 month after
therapy.
Instruct male
patients to use
barrier contraception
during and for 3
months after therapy.
As appropriate,
review all other
significant and life-
threatening adverse
reactions and
interactions,
especially those
related to the drugs
and tests mentioned
above.